Language: BG BG
← Back to results
Not yet recruiting Phase 3 NCT07525219

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

Phase 3 – large-scale trial before approval
Conditions: Analgesic Efficacy

Sponsor: Wake Forest University Health Sciences

trial.available_in: БГ
Overview
Local anesthetic infiltration is a primary source of acute pain during stereotactic procedures.
Description
Frame placement can be painful even with local numbing medicine. This study compares two oral medications-Suzetrigine (an FDA-approved (January 30, 2025) non-opioid, non-addictive medication used to treat moderate-to-severe acute pain in adults)) and acetaminophen (Tylenol)-to see which is more effective at reducing this pain. Both Tylenol and Suzetrigine are currently being used for pain prevention during head frame placement. This study is being conducted to determine if one offers greater relief than the other.
Who can participate
Inclusion Criteria: * Patients scheduled for a standard of care procedure requiring a stereotactic head frame to be placed Exclusion Criteria: * Patients not scheduled for a standard of care procedure requiring a stereotactic head frame to be placed will not be approached
Interventions
Suzetrigine
DRUG
acetaminophen
DRUG
Locations 1
United States (1)
Wake Forest University Health Sciences
Winston-Salem , North Carolina
Technical details
Status
Not yet recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
21 Years
Healthy volunteers
No
Start date
01.07.2026
Completion date
01.07.2027
Registry ID
NCT07525219
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.